Previous close | 1.3205 |
Open | 1.3300 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 1.3200 - 1.3582 |
52-week range | 0.4350 - 1.3582 |
Volume | |
Avg. volume | 10,353 |
Market cap | 2.297M |
Beta (5Y monthly) | 0.91 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.6640 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.